imc@healthandcommerce.com, Author at Corcept Therapeutics - Page 7 of 16

About imc@healthandcommerce.com

This author has not written his bio yet.
But we are proud to say that imc@healthandcommerce.com contributed 159 entries already.

Entries by imc@healthandcommerce.com

Phase 2 Results of Relacorilant + Nab-Paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer with and Without Prior Bevacizumab

Colombo et al • 2022 • International Gynecologic Cancer Society 2022 Annual Meeting

February 13, 2023

Glucocorticoid Receptor Expression and Activity in a Phase 2 Ovarian Cancer Trial of the Glucocorticoid Receptor Modulator Relacorilant in Combination with Nab-Paclitaxel

Lorusso et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022

February 12, 2023

Phase 1 Results of Exicorilant + Enzalutamide in Patients with Castration-Resistant Prostate Cancer

Linch et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022

February 11, 2023

Relacorilant + Nab-paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer: Phase 2 Subgroup Analysis Mirroring the Patient Population of an Upcoming Phase 3 Study

Colombo et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022

February 10, 2023

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

Munster et al • 2022 • Clin Cancer Res OF1–OF11

February 9, 2023

Hypercortisolism (Cushing syndrome)

Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with Cushing Syndrome

Moraitis et al • 2022 • ENDO 2022 Annual Meeting

February 8, 2023

Hypercortisolism (Cushing syndrome)

Impact of mifepristone on liver function and liver steatosis in patients with Cushing Syndrome

East et al • 2022 • ENDO 2022 Annual Meeting

February 7, 2023

Overall survival data from a 3-arm, randomized, open-label phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer

Colombo et al • 2022 • American Society of Clinical Oncology Annual Meeting

February 6, 2023

A study of relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)

Borazanci et al • 2022 • American Society of Clinical Oncology Annual Meeting

February 5, 2023

DAZALS: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis

Mann et al • 2022 • European Network to Cure ALS (ENCALS)

February 3, 2023